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Abstract
Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative
disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood.
Accordingly, we have assessed how proteasome dysfunction during early postnatal development, induced by administering
proteasome inhibitors daily during the first 10 days of life, affects the behaviour of adult mice. We found that this regime of
exposure to the proteasome inhibitors MG132 or lactacystin did not produce significant behavioural or morphological
changes in the first 15 days of life. However, towards the end of the treatment with proteasome inhibitors, there was a loss
of mitochondrial markers and activity, and an increase in DNA oxidation. On reaching adulthood, the memory of mice that
were injected with proteasome inhibitors postnatally was impaired in hippocampal and amygdala-dependent tasks, and
they suffered motor dysfunction and imbalance. These behavioural deficiencies were correlated with neuronal loss in the
hippocampus, amygdala and brainstem, and with diminished adult neurogenesis. Accordingly, impairing proteasome
activity at early postnatal ages appears to cause morphological and behavioural alterations in adult mice that resemble
those associated with certain neurodegenerative diseases and/or syndromes of mental retardation.
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Introduction
Postnatal brain development is a critical period during which
synaptic connections are formed and refined. In the rodent
hippocampus, many of these connections reach maturity by the
end of the second postnatal week, following an identifiable
developmental progression that appears to be common to a wide
variety of species [1–3]. Insult or injury to the brain during this
time may have significant consequences, manifested as behaviour-
al changes due to the modifications in brain structure and function
[4,5]. Indeed, prenatal exposure to either environmental stress [6]
or chemical toxins [7] may produce long-lasting behavioural
changes. Thus, rats exposed to neurotoxic compounds during the
first few weeks of postnatal development display spontaneous
recurrent seizure activity upon reaching adulthood, evident both
behaviourally and in electroencephalographic analyses [8,9].
Exposure to such toxins also provokes the formation of a
hyperexcitable hippocampal network in vitro [10,11]. Similarly,
deprivation of maternal care during the first week of life provokes
emotional and cognitive behavioural alterations in rodents that are
ultimately manifested in adults [12].
Proteins are the motors of virtually all biological processes, and
the finely tuned equilibrium between their synthesis and
degradation influences cellular homoeostasis. Accordingly, the
deregulation of protein clearance and synthesis contributes to cell
senescence, aging and various age-related disorders in the central
nervous system [13–17]. Proteins that are of no use to a cell are
disposed of through the ubiquitin proteasome system (UPS) [18],
including mutant, misfolded, damaged, terminally modified or
over-accumulated proteins [19]. The proteasome also degrades
proteins involved in cellular processes such as signal transduction,
cell-cycle regulation, metabolism, inflammation and apoptosis
[20–22]. There is growing evidence that protein degradation has a
strong influence on both neuronal development and long-term
synaptic plasticity [23–27]. Indeed, the abnormal protein
aggregates observed in many neurodegenerative diseases, such as
Alzheimer’s, Huntington’s and Parkinson’s diseases, reflect the
dysfunctional protein degradation in these pathologies [28,29].
In the last decade, considerable research has focused on the
role of the UPS in aging, neurodegenerative diseases and synaptic
plasticity. Here we focus on the role of the UPS during early
postnatal mouse development and on the consequences of
postnatal proteasome inhibition in later life. To address these
issues, we administrated proteasome inhibitors in the temporal
window from 1 to 10 days life as in this period the blood brain
barrier is not completely closed and as such, proteasome
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28927inhibitors can reach the brain easily. Subchronic administration
of the proteasome inhibitors MG132 or lactacystin provoked a
significant decrease in chymotrypsin activity, an accumulation of
ubiquitinated proteins, a decrease in mitochondrial markers and
of their activity, and an increase in DNA oxidation. However,
proteasome inhibition caused no behavioural or morphological
alterations within this timeframe. Nevertheless, upon reaching 3–
5 months of age, mice treated postnatally with proteasome
inhibitors displayed impaired hippocampal- and amygdala-
cognition, and mild motor dysfunction. These behavioural
deficiencies were correlated with neuronal loss in the hippocam-
pus, amygdala and brainstem, as well as diminished neurogenesis.
Accordingly, these results indicate that decreased UPS function
during early postnatal development provokes an acceleration of
several features associated with aging, including neuronal
degeneration, as well as motor and cognitive impairment,
inducing a phenotype similar to that found in mouse models of
mental retardation.
Results
Systemic administration of proteasome inhibitors in
neonates decreases proteasomal and mitochondrial
activity, and it increases DNA oxidation in the mouse
brain, without affecting early psychomotor development
To study the effect of early postnatal proteasome inhibition on
adult mice during the first 10 days of life, we administered daily
systemic injections of a proteasome inhibitor, MG132 (2.5 mg/kg)
or lactacystin (1 mg/kg). To quantify the effect of proteasome
inhibition on ubiquitinated proteins, western blots of total brain
protein from PD10 mice were probed with an antibody against
ubiquitin. Ubiquitinated proteins were more abundant in brain
extracts from MG132- and lactacystin-treated mice than in their
respective controls (MG132: t(6)=4.679, p=0.003; Lactacystin:
t(6)=4.605, p=0.004. Fig. 1A). To confirm that the proteasome
had been inhibited, chymotrypsin proteasomal activity was
measured in the brains of PD10 mice treated with proteasome
inhibitors. Both MG132- and lactacystin-treated mice exhibited a
significant decrease in chymotrypsin activity when compared with
the control mice (MG132: t(9)=8.456, p,0.001; Lactacystin:
t(9)=2.814, p=0.002. Fig. 1B). Hence, the two proteasome
inhibitors used appear to reach the brain and effectively inhibit
proteasome activity.
We investigated the effects of proteasome inhibition on
other molecular processes, focusing initially on the mitochondria
as there is evidence that mitochondrial quality is controlled
by the ubiquitin-proteasome system [30,31]. Early postnatal
inhibition of proteasome activity diminished the amount of
prohibitin detected by immunohistochemistry, an integral
protein of the inner mitochondrial membrane (22.2660.6,
17.1760.87 and 18.3661.13 arbitrary units in control, MG132
and lactacystin-treated mice respectively: F(10, 2)=12.21,
p=0.002. Fig. 2A). Similarly, citrate synthase activity was also
reduced (40.0561.39, 33.2560.67 and 32.3162.22 mg/mg in
control, MG132- and lactacystin-injected mice, respectively:
F(21, 2)=8.71, p=0.001. Fig. 2B). Together, these results
suggest that the administration of proteasome inhibitors
decreased the number and/or activity of mitochondria, an effect
that would probably induce oxidative stress [32]. Hence, we
assessed the oxidative stress in these mice by evaluating the
presence of 8-OH-deoxyguanine (8-OH-dG) in the total DNA
extracted from control, MG-132- and lactacystin-injected mouse
brains. Proteasome inhibition during early postnatal development
augmented 8-OH-dG immunoreactivity (5.1861.8 in MG132-
and 4.7361.64 fold in lactacystin-treated mice relative to the
controls: F(19, 2)=4.36, p=0.02.Fig. 2C). These results suggest
that proteasome inhibition during early postnatal development
provokes mitochondrial dysfunction and increased oxidative
stress.
To determine the effect of proteasome inhibition on the
postnatal psychomotor development of mice, we performed
behavioural tests included in the Fox’s battery daily from PD 1
to 15 (Fig. S1). In terms of balance reflexes (measured through the
righting reflex, cliff drop aversion, negative geotaxia or the
suspension test: Fig. S1B, C and E) or locomotor activity
(pivoting activity test: Fig. S1D), there were no significant
differences between mice injected with proteasome inhibitors
and control mice during the first two weeks of life. Moreover,
while some differences in the body weight of MG132-treated mice
were observed initially (Fig. S1A), these disappeared later with
age. When brain morphology was analyzed by staining with
antibodies against calbindin, tyrosine hydroxylase and doublecor-
tin, there were no significant differences in the hippocampus,
cerebellum, amygdala or substantia nigra of PD15 mice treated
with proteasome inhibitors when compared to their control
littermates (Fig. S2).
Figure 1. Proteasome inhibition during early postnatal development provokes the accumulation of ubiquitinated proteins. Mouse
pups were treated with vehicle, MG132 or lactacystin for the first 10 days of life. One hour after the last injection, pups were sacrificed and total brain
protein was extracted. A Representative western blot probed for ubiquitin and optical densitometry quantification of ubiquitinated proteins in
vehicle-, MG132- and lactacystin-injected pups (left and right panels, respectively). B Chymotrypsin proteasome activity in control, MG132 and
lactacystin treated pups (black, gray and white bars, respectively). n=5 per group. *, p,0.05, **, p,0.01, ***, p,0.001.
doi:10.1371/journal.pone.0028927.g001
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development induces mild alterations in exploratory
activity in adult mice
To determine whether temporary inhibition of proteasome
activity during the first 10 days of life produces behavioural
alterations in adult mice, exploratory activity in 3–5 month old mice
was evaluated over 5 minutes in the open field test. Mice treated
with proteasome inhibitors exhibited a mild non-significant
decrease in locomotor activity when compared with control mice
(Fig. 3A). The capacity to habituate to a new environment was
evaluated as the ratio of activity in the first and last minute in the
open field (Fig. 3B). This habituation index (H) was higher in mice
treated postnatally with proteasome inhibitors than in control mice
(MG132: t(23)=0.041, p=2.15; lactacystin: t(23)=0.032, p=2.26).
These findings suggest that proteasome inhibition during early
postnataldevelopmentprovokescognitivedeficienciesinadulthood.
Proteasome inhibition during early postnatal
development results in mild symptoms of depression,
decreased co-ordination and a loss of brainstem
dopaminergic neurons in adult mice
To study cognition in adult mice subjected to postnatal
proteasome inhibition, 3–5 month old mice were subjected to
tests of anxiety-like behaviour in the elevated plus maze, which
revealed no differences between mice treated with proteasome
inhibitors and their controls (Fig. 4A). Moreover, immobility in
the tail suspension test was used to measure depression-like
behaviour, which revealed increased immobility in mice treated
with proteasome inhibitors when compared to their controls
(Fig. 4B). The tail suspension test can also reveal balance
impairment that may result from a loss of brainstem dopaminer-
gic neurons. Interestingly, more of the mice treated with
proteasome inhibitors as neonates exhibited spasmodic move-
ments (53.3% and 27.27% of MG132- and lactacystin-injected
mice, respectively) and limb clasping (33.3% and 72.72% of
MG132- and lactacystin-injected mice, respectively: Fig. 5A). As
this abnormal motor behaviour could be attributed to the motor
dysfunction found in mouse models for motor neuron diseases, we
performed specific behavioural tests for motor dysfunction:
Rotarod, treadmill, and grip strength (Fig. S3A–C). No
significant differences were found in vehicle-, MG132- and
lactacystin-injected mice in any of these tests. Furthermore, when
we studied the histology of the spinal cord, there were no
differences between these three experimental groups (Fig. S3D).
Hence, mice treated with proteasome inhibitors during postnatal
development appear to suffer depression and altered motor
coordination in adulthood.
Figure 2. Proteasome inhibition during early postnatal development provokes a decrease in the expression of mitochondrial
markers and an increase in DNA oxidation. Mouse pups were treated with the vehicle alone, MG132 or lactacystin for the first 10 days of life
and 1 hour after the last injection, the pups were killed and their brains removed. A Representative immunohistochemistry and optical densitometry
quantification of prohibitin in pups treated with the vehicle alone, MG132 or lactacystin (black, gray and white bars, respectively). B Citrate synthase
activity in brain protein extracts from control, MG132 or lactacystin treated pups. C Representative dot blot and optical densitometry quantification
for 8-OH-deoxyguanine (8-OH-dG), a marker of DNA oxidation, in total DNA extracted from the brains of control, MG132 or lactacystin treated mice.
n=5 per group. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0028927.g002
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tegmental area (VTA) dopaminergic neurons in regulating
movement co-ordination, we assessed the levels of tyrosine
hydroxylase (TH) protein by immunohistochemistry. Fewer TH
+
neurons were detected in the SN and VTA of adult mice treated
postnatally with lactacystin than in control mice (SN: t (15)=
4.351, p,0.001; VTA: t (15)=6.846, p,0.001. Fig. 5B).
Similarly, adult mice treated neonatally with MG132 had fewer
TH
+ neurons in the VTA (t (15)=3.954, p,0.001). These
decreases in the number of TH
+ neurons in the SN and VTA
were probably correlated with the severity of the impairments in
their co-ordination.
Adult mice treated with proteasome inhibitors during
early postnatal development exhibit memory defects and
neuronal loss in the hippocampus and amygdala
To identify possible cognitive deficiencies in adult mice
treated postnatally with proteasome inhibitors, as suggested by
the exploratory habituation findings, we performed several
learning and memory tests that depend on different brain areas.
In the hippocampal-dependent Y-maze, we evaluated the
preference of the mice for the novel arm of the maze. Animals
treated with proteasome inhibitors at early ages showed a
weaker preference for the novel arm than control mice
(1.8860.11, 1.2260.1 and 1.3160.03 for vehicle-, MG132-
and lactacystin-treated mice, respectively: F(39, 2)=11.46,
p,0.001. Fig. 6A). The object recognition memory test, a one
trial test also dependent on hippocampal function, revealed
that adult mice treated postnatally with proteasome inhibitors
had impaired long-term memory (LTM), evaluated 24 hours
after the training session (the discrimination indices were
0.3560.03, 0.1560.04 and 0.1560.09 in vehicle-, MG132-
and lactcystin-treated mice respectively: F(28, 2)=6, p=0.006.
Fig. 6B). By contrast, no effects on short-term memory (STM)
were observed 1 hour after the training session (F(28, 2)=0.71,
p=0.49). Furthermore, proteasome inhibitor treatment failed to
alter the exploration times with respect to the vehicle treated
group in the OR test (Table S1). Finally, mice were subjected to
the hot plate passive avoidance test, an amygdala-dependent
learning and memory test. The avoidance index for STM
revealed that all experimental animals learned the task
irrespective of the treatment administered (43.3468.88%,
49.41619.25%, and 51.02614.16% for mice treated with
the vehicle alone, MG132 and lactacystin, respectively:
F(21.2)=0.08, p=0.92. Fig. 6C). However, adult mice treated
postnatally with proteasome inhibitors had a lower avoidance
index in the LTM test than the control mice (42.36612.05%,
11.3363.32%, and 11.3563.43% mice treated with the vehicle
alone, MG132 and lactacystin, respectively: F(21,2)=5.72,
p=0.01).
As the hippocampus and amygdala play central roles in learning
acquisition and memory consolidation in the tests used, these
structures were analysed morphologically by calbindin immuno-
histochemistry. In both structures, fewer neurons expressing
calbindin were observed in adult mice treated postnatally with
proteasome inhibitors when compared to the controls (Fig. 7A
and 8). As adult hippocampal neurogenesis (AHN) appears to be
involved in behavioural alterations and neuronal plasticity, we
analyzed neurogenesis by doublecortin (DCX) immunohistochem-
istry. The number of neurons in the hippocampus labelled for
DCX was significantly lower in adult mice treated postnatally with
proteasome inhibitors than in control animals (Fig. 7B). These
results suggest that mice treated with proteasome inhibitors during
postnatal development experience premature neuronal loss in the
hippocampus and amygdala, which may account for the impaired
cognitive abilities observed.
Figure 3. Effect of postnatal proteasome inhibition on
exploratory activity in adult mice. A Total motor activity of mice
treated with the vehicle alone, MG132 and lactacystin (black, gray and
white symbols, respectively), as measured in an open field for
5 minutes. B Minute-by minute evolution of motor activity over
5 minutes in the same experimental animals. The habituation index
was determined as the ratio between the activity in the last and the first
minute in the open field. n=15, 10 and 10 in control, MG132, and
lactacystin treated groups, respectively. **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0028927.g003
Figure 4. Proteasome inhibition during early postnatal devel-
opment induces depression-like symptoms in adult mice. The
behaviour of mice treated postnatally with proteasome inhibitors was
assessed in the elevated plus maze (A) and tail suspension test (B). A,
The time (s) and number of entries into the open and closed arms was
measured over 5 minutes. B, Accumulated time spent immobile (s) over
5 minutes in the tail suspension test. Black, gray and white bars or
circles represent mice treated with the vehicle alone (n=15), MG132
(n=10) and lactacystin (n=11), respectively. *, p,0.05.
doi:10.1371/journal.pone.0028927.g004
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The UPS provides a useful mechanism to dispose of
biologically compromised proteins in a cell, including mutant,
misfolded, damaged, terminally modified or over-represented
proteins [19]. In addition to this waste basket-like function, the
UPS provides a highly specific means of controlling the
expression of proteins involved in signal transduction pathways,
in cell–cell communication during neuronal development, in
Figure 5. Proteasome inhibition during early postnatal devel-
opment provokes discoordination and a loss of brainstem
dopaminergic neurons in adult mice. A (Upper panel) photograph
showing examples of limb extension, spasmodic movement and limb
clasping during the tail suspension test. Bar graph represents the
percentage of mice exhibiting each behaviour in the tail suspension
test for each experimental group. Black, gray and white bars represent
mice treated with the vehicle alone (n=14), MG132 (n=15) and
lactacystin (n=11), respectively. B Representative photomicrograph
showing brainstem dopaminergic neurons in mice treated with the
vehicle alone, MG132 and lactacystin. Bar graph showing the density of
dopaminergic neurons (neurons/mm
2) in the susbtantia nigra (SN) and
ventral tegmental area (VTA) in the same experimental groups as those
shown in A. n=8 mice per group. *, p,0.05; ***, p,0.001.
doi:10.1371/journal.pone.0028927.g005
Figure 6. Memory deficiencies in adult mice treated postnatally
with proteasome inhibitors. Cognitive capacity was assessed in
adult mice treated postnatally with proteasome inhibitors using the Y
maze (A), object recognition test (B) and passive avoidance test (C). A,
New arm preference in the Y maze was assessed during a short term
memory test performed 2 minutes after a 10 minute training session
(n=16, 15 and 11 in control, MG132 and lactacystin treated animals,
respectively). B, Discrimination index in short- and long-term (STM and
LTM) memory training sessions in the object recognition test (n=14, 11
and 6 in control, MG132 and lactacystin treated animals, respectively).
C, Avoidance index during STM and LTM training sessions in the hot
plate passive avoidance test (n=8 mice per group). * indicates
significant differences between the STM or LTM session compared
with the training session; + indicates significant differences between
groups in the same session. Black, gray and white bars represent mice
treated with the vehicle alone, MG132 and lactacystin, respectively.
*o r
+, p,0.05; ** or
++, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0028927.g006
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synaptic plasticity [23–26,33,34]. Abnormal protein aggregates,
including those containing polyubiquitinated protein, are associ-
ated with aging and with many neurodegenerative diseases, such
as Alzheimer’s, Huntington’s and Parkinson’s diseases, suggesting
that UPS dysfunction may be implicated in these diseases [28,29].
Figure 7. Hippocampal neuronal loss and deficient neurogenesis in adult mice treated postnatally with proteasome inhibitors. A,
Hippocampal integrity was assayed by calbindin immunohistochemistry. Representative photomicrograph showing different antero-posterior
hippocampal levels in adult mice treated postnatally with the vehicle alone, MG132 or lactacystin (n=8 per group). B, Neurogenesis was evaluated
by doublecortin (DCX) immunohistochemistry. Representative photomicrographs of DCX immunoreactivity in the hippocampal dentate gyrus are
shown and the histograms show the stereological quantification of DCX
+ neurons in the subgranular layer of the dentate gyrus. Black, gray and white
bars represent mice treated with the vehicle alone, MG132 and lactacystin, respectively (n=8 per group). *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0028927.g007
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dysfunction in aging and neurodegenerative diseases, the
consequences of postnatal inhibition of the UPS in adult mice
have been little studied. As such, we focused on the role of the
proteasome during early postnatal development (PD 1–10) and
the consequences of its inhibition during this period in adult
mice. Interestingly, administering proteasome inhibitors during
early development caused no immediate alterations in behaviour
that could be detected in the Fox test. However, upon reaching
adulthood, mice treated postnatally with proteasome inhibitors
exhibited a complex behavioural phenotype, with features of
depression, motor discoordination, and cognitive alterations in
several learning and memory tests. Many of these behaviours are
also associated with neurodevelopmental and mental retardation
disorders.
At the cellular level, motor co-ordination and cognitive
deficits are linked to functional impairment in specific brain
areas. Motor co-ordination is primarily linked to the brainstem,
striatum and cerebellum, as evident through the characteristic
motor disturbances associated with neurodegeneration in these
areas in Parkinson’s and Huntington’s diseases, and in ataxia
[35–37]. Morphological analysis of the brains of adult mice
treated postnatally with proteasome inhibitors revealed a
decrease in the density of dopaminergic neurons in the brainstem.
Furthermore, the severity of motor discoordination was correlat-
ed with the loss of these dopaminergic neurons. Indeed,
dopaminergic neurons were lost in both the substantia nigra
and VTA of lactacystin treated mice, while only the latter was
affected in MG132 treated mice. A decrease in the number of
calbindin positive neurons was also observed in the hippocampus
and amygdala of mice treated postnatally with proteasome
inhibitors, both these regions playing a critical role in different
learning and memory tasks: the amygdala is involved in
emotional cognition [38,39]; and the hippocampus in spatial
and associative cognition [40,41]. Interestingly, postnatal protea-
some-inhibition impaired long-term memory as evident in
the object recognition and the passive avoidance test. By contrast,
alterations to short-term memory following proteasome inhibition
were observed in open-field habituation and the Y maze, tests
of hippocampal function [42]. Finally, postnatal proteasome
inhibition also produced depression-like symptoms in adult-
hood, as well as a decrease in AHN. A correlation between
neurogenesis and depression has already been described [43–45],
and AHN has been linked with learning consolidation [46].
Hence, a decrease in the neurogenic response provoked by
proteasome inhibition could contribute to the impaired learning
consolidation. Together, these findings suggest that morpholog-
ically undetectable alterations in neonatal brain development
induced by proteasome inhibition may form the basis of a variety
of different neurological pathologies in adults. In agreement,
several neurodevelopmental diseases, mental retardation and
schizophrenia, have all been linked to proteasome deficiencies
[47].
The early postnatal period is a critical stage of brain
development during which excitatory and inhibitory functions
in the brain are organized and mature. For this reason,
environmental stress or exposure to excitatory toxins during this
period can provoke behavioural alterations in adulthood
[6,48,49]. The cellular and molecular bases of these long-term
effects remain poorly understood. Reduced maternal care has
been shown to provoke persistent alterations in gene expression,
probably due to long-term modifications in gene methylation
profiles [12,50], and these alterations are correlated with
depressive-like behaviour in later life. In the present study, we
demonstrate that postnatal proteasome inhibition causes long-
term behavioural and morphological alterations in adult mice.
These alterations may result from a decrease in mitochondrial
activity together with an increase in DNA oxidation, both of
which appear to be associated with proteasome inhibition in the
brain of PD15 mice. Proteasome inhibition reduces complex I
and complex II activity, and intra-mitochondrial protein
translation, while it increases the production of mitochondrial
reactive oxygen species. In addition, impaired UPS activity alters
mitochondrial DNA and impairs mitochondrial turnover [51,52].
Any or all of these events may occur in the postnatal brain in
response to proteasome inhibition, representing the starting point
for the neurodegeneration observed in the subtantia nigra,
amygdala and hippocampus when these animals reach adult-
hood. Our results are supported by similar findings in the adult
brain of conditional psmc1 knockout mice, in which the activity
of the 26S proteasome is impaired. In these mice, deficiencies in
proteasome activity result in early and lethal neurodegeneration,
beginning at 3–4 weeks of age [53].
Proteasome dysfunction is considered a key contributor to
aging-associated neurodegeneration. Indeed, brains from aging
individuals and/or those suffering neurodegeneration exhibit clear
deficiencies in proteasome activity. Furthermore, mutations in
some of the components of the proteasome pathways have been
linked to neurodegeneration, mental retardation and other
neurodevelopmental diseases. Together, our results demonstrate
that subchronic proteasome inhibition during early postnatal
development, probably through mitochondrial dysfunction, trig-
gers the development of a complex behavioural phenotype that is
correlated with degeneration in specific brain areas. This
phenotype shares many features with mental retardation syn-
dromes, suggesting that proteasome dysfunction plays a critical
role in the development of these syndromes.
Figure 8. Proteasome inhibition during early postnatal devel-
opment provokes a loss of calbindin neurons in the amygdala
of adult mice. Amygdala integrity was assayed by calbindin
immunohistochemistry (Representative photomicrograph showing the
amygdala of adult mice treated postnatally with the vehicle alone,
MG132 or lactacystin). Bar graph shows neuronal density (neurons/
mm
2) in the amygdala in each experimental group. Black, gray and
white bars represent control, MG132 and lactacystin treated mice,
respectively (n=8 mice per group). ***, p,0.001.
doi:10.1371/journal.pone.0028927.g008
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Animals
Swiss mice weighing 25–30 g were obtained from University of
Seville animal facilities and used as the parental mice. The mice
were maintained under standard housing conditions, at 2161uC
with a photoperiod of 12:12 h (lights on at 07:30 h), and using dust-
free sawdust. Food pellets and water were available ad libitum.
Breeding pairs were formed and females were isolated when visibly
close to parturition. Litters were adjusted to a maximum of ten pups
in order to avoid any effects of parity on behavioural ontogeny [54].
General procedure for postnatal observations
All pregnant dams were allowed to deliver spontaneously. The
day of birth was designated as postnatal day (PD) 0 (66 h). On
delivery, the litter size of each dam was recorded and each pup
was checked for gross abnormalities. Pups were individually
marked with India ink on PD1 and nursed by their natural dams
until weaning. From PD 1 to 10 (inclusive), the pups were weighed
and subcutaneously administered proteasome inhibitors daily
(2.5 mg/kg of MG132 or 1 mg/kg of lactacystin, injected under
the skin back) or the vehicle alone (DMSO for MG132 or saline
for lactacystin). After weaning, the mice were allowed to grow to
3–5 months of age in groups of 4–5. Upon reaching adulthood
(from 3 to 5 months old), cognitive behavioural tests were
performed. The sex distribution of the treatments was random and
while histological analysis at P15 was performed mainly on female
mice, adult behaviour and histology were performed on male mice
in order to avoid the oestrus cycle. All experimental protocols were
approved by the Ethics Committee of the Pablo de Olavide
University (07/4-20/12/2008), in accordance with the European
Community guidelines (86/609/EEC amended by Directive
2005/65/EC) and the Spanish regulations for the procurement
and care of experimental animals (1201 RD/2005, October 10).
Neonatal behavioural tests
During the testing protocols included in the Fox battery [55],
whole litters were separated from the dams and maintained for
30 min in a warm environment. Males and females were pooled
for neurodevelopmental screening after preliminary experiments
demonstrated that there was no significant effect of sex. The range
of ages at which responses were observed was evaluated in
preliminary experiments in order to define the period of
observation and to reduce handling. All testing was performed
between 07:30 a.m. and 12:00 a.m. After completing the
experimental procedure with each litter, the mice were weighed,
injected and returned to the mother. The neonatal behavioural
tests are described in Methods S1.
Behavioural testing of adult mice
Behavioural tests were performed in a room with homogeneous
sound and light. To eliminate any odours or traces that might
affect the outcome of the test, the behavioural apparatus was
cleaned with 70% ethanol (Panreac Quı ´mica S.A.U) between the
testing of each animal. The order in which the tests were run was
always the same: Open field, object recognition memory, Y maze,
plus maze, tail suspension and step down passive avoidance.
Motor activity in the open field. To evaluate locomotor
and exploratory activity, mice were placed for 5 minutes in an
open field (38621615 cm) (Cybertec S.A.). This apparatus
consisted of a walled platform containing infrared emitters and
sensors (IR) coupled to an actimeter, and the movement sensor
was connected to a computer that recorded the number of times
the mouse interrupted the IR beams/min.
Elevated plus maze. The elevated plus maze consisted of
two open and two closed arms of equal dimensions extending from
a central area, and it was elevated 70 cm above the ground. Mice
were placed at the end of the open arm in brightly lit conditions
and allowed to explore the maze for 5 minutes. The percentage of
entries and the time spent in the open and closed arms were
measured.
Y maze. The Y maze used had three equal sized arms
(8640620 cm), the walls of which were decorated with different
patterns to enable the mice to discriminate between the arms.
Mice were allowed to freely explore two arms during a 10 minute
training session, after which they were returned to their cages for
2 minutes while olfactory cues were cleaned from the maze.
Subsequently, mice were returned to the maze and allowed to
explore all three arms for 10 minutes. Short-term memory was
determined as the number of entries into the new arms/average
number of entries into the familiar arms.
Object recognition memory. Mice were tested in a
rectangular arena (55640640 cm) located in a room with dim
lighting and constant background noise. For the object recognition
protocol, two different objects were placed in the arena during the
training phase. The animal’s memory of the original object was
assessed by comparing the amount of time spent exploring the novel
object against that for the familiar one. The objects consisted of
plastic pieces of different shapes and they were cleaned thoroughly
with 70% ethanol between trials to remove any olfactory cues.
Before the experiment, mice were habituated to the arena for
20 min in the absence of the objects on 2 consecutive days. On the
day of training, mice were allowed 15 min to explore the two
objects. Retention tests were then performed at the times indicated
after the training session by placing the mice back in the arena for a
10 min session after randomly exchanging one of the familiar
objects for a novel object. The time spent exploring each object was
recorded and the relative exploration of the novel object was
expressed by a discrimination index [DI=(tnovel2tfamiliar)/
(tnovel+tfamiliar)]. The criteria for exploration were based strictly on
active exploration. Exploration of an object was defined as directing
the nose toward the object at a distance of 61.5 cm and/or
touching the object with the nose or vibrissae. Circling or sitting on
the object were not considered exploratory behaviour. All trials
were performed by an experimenter blind to the drug treatments.
Step down passive avoidance. This learning test was
performed on a hot plate placed inside a rectangular chamber
(15615621 cm), which contained a step that allowed the mice to
avoid the negative stimulus (a heat shock of 6060.5uC). After a
habituation session in the absence of a negative stimulus, mice
were subjected to a training session in which they were placed on
the step and the time taken to descend was determined. Each
session lasted 30 seconds. By leaving the animal on the platform
and quantifying the time taken to step off in the absence of a heat
stimulus, short- and long-term memory were evaluated 10 minutes
and 24 hours after finishing the training session, respectively. The
response inhibition was calculated as the percentage of the total
time the mice spent on the step.
Tail suspension. Mice were suspended above the floor by
fixing the end of the tail to wire netting and immobility was scored
by manual observation during a 5 min test session. Motor co-
ordination was also scored, as revealed by the movements made to
maintain balance (i.e.: spasmodic movements or limb clasping).
Tissue Preparation and Immunohistochemistry
To quantify the morphological alterations in the brain induced
by treatment with proteasome inhibitors, mice from each
experimental group were sacrificed by decapitation, and their
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4% paraformaldehyde prepared in phosphate-buffered saline
(PBS). The tissue was cryoprotected in 30% sucrose-PBS for 2
days at 4uC and coronal brain sections (50 mm) were then
processed for free-floating immunohistochemistry [56] using
specific antisera against: calbindin (Swant Antibodies, diluted
1:3,000), tyrosine hydroxylase (TH, Pel-Freez Biologicals, diluted
1:3,000), doublecortin (DCX, Santa Cruz Biotechnologies, diluted
1:1,000), and prohibitin (Epitomics, diluted 1:500). Densitometry
and quantification of the neurons in the sections were performed
using Image-J software (downloaded as a free software package
from the public domain: http://rsb.info.nih.gov/ij/download.
html). For DCX immunostaining we performed stereological
quantification using an optical dissector to measure cell density.
The volume of the subgranular layer of the dentate gyrus was
measured by the standard Cavalieri method with the aid of
ImageJ. By multiplying the mean cell density and the total
reference volume for each animal, the total number of cells per
animal was obtained.
Protein extraction
Fresh brain areas were dissected at 4uC and homogenized by
sonication for 15 seconds in 1 mL of cold lysis buffer: 10 mM
Tris-HCl (pH 7.8), 0.5 mM DTT, 5 mM MgCl2. The lysates were
centrifuged at 4006g for 10 minutes at 4uC, 20% glycerol was
added to the protein supernatant obtained and the samples were
stored at 280uC. Protein quantification was performed using the
BioRad protein assay (Bio-Rad Laboratories, Inc).
Proteasome activity assay
The fluorogenic substrate Succ-LLVY-AFC (N-Succinyl-Leu-
Leu-val-Tyr 7-Amido 4trifluormethylcoumarin, Sigma Aldrich)
was used to measure chymotrypsin-like proteasome activity. Assays
were carried out at 37uCi na5 0ml reaction volume containing:
12.5 mg protein extract, 5 mM ATP (AppliChem GmBH), 50 mM
EDTA (Sigma), and 5 mM Succ-LLVY-AFC in lysis buffer. The
rate of cleavage of the fluorogenic peptide substrates was
determined in a multiwell plate reader (Varioskan flash-Termo
Fisher Scientific) by monitoring the fluorescence of the fluor-
omethylcoumarin released every 5 minutes over 1 hour, with an
excitation wavelength of 395 nm and emission wavelength of
460 nm. Proteasome activity was expressed as the slope of the
enzymatic kinetics.
Measurement of citrate synthase activity
The specific activity of citrate synthase in cell extracts prepared
from brain tissues was measured at 412 nm minus 360 nm
(13.6 mmol/L/cm) using 5,5-dithio-bis(2-nitrobenzoic acid) to
detect free sulfhydryl groups in coenzymeA, as described
previously [57].
Immunoblotting
For dot blots, 5 mg of DNA from mouse brains was digested
with EcoRI and heat denatured. DNA was diluted in 200 mlo f6 6
SSC and transferred to a nitrocellulose membrane using a Bio-Dot
SF Microfiltration Apparatus (Bio-Rad). Protein extracts from the
areas selected were resolved on 10% polyacrylamide gels for SDS–
PAGE electrophoresis and subsequently transferred to PVDF
membranes. After blocking, the membranes were probed
overnight at 4uC with a primary goat polyclonal antiserum against
8-hydroxy-2-deoxyguanosine (1:500, Millipore) for dot blots, or
with a primary polyclonal antiserum against ubiquitin (Dako) or
actin (Santa Cruz Biotechnologies) diluted 1:1,000. Antibody
binding was visualized with the ECL plus kit (Amersham
Biosciences).
Statistical Analysis
Statistical analyses were performed using the SPSS package for
Windows (SPSS, Chicago, IL). Unless otherwise indicated, the
data are represented as the mean 6 SEM. Two-way analysis of
variance (ANOVA) was used to compare behavioural results from
animals treated with the vehicle alone or the proteasome
inhibitors. Chi-squared tests were used for statistical analysis in
cases where the qualitative variables were compared.
Supporting Information
Figure S1 Postnatal proteasome inhibition had no effect
on body weight or neurobehavioural activity. A The body
weight of animals treated with proteasome inhibitors evolved
similarly to that of mice that received the vehicle alone, except
for a small decrease in P9-10 mice treated with MG132
[t (28)=2.233, P=0.034], which was subsequently reversed. B–
E, Fox Battery tests carried out in animals treated with
proteasome inhibitors revealed no significant differences with
respect to the group that received the vehicle alone in terms of the
righting reflex (B), negative geotaxia (C), rotating activity (D) or
muscle strength in the suspension test (E). Taken together these
data, suggest that proteasome inhibition during early postnatal
development does not affect the pup’s behaviour.
(TIF)
Figure S2 Postnatal proteasome treatment caused no
morphological alterations at PD15. At PD15, mice treated
with proteasome inhibitors or the vehicle alone were sacrificed,
and their brain histology was analysed. A–C Immunohistochem-
istry for calbindin revealed no differences in hippocampal
dendritic morphology (A) in either the cerebellum (B) or amygdala
(C) of mice treated with proteasome inhibitors, or with the vehicle
alone. D Tyrosine hydroxylase immunohistochemistry revealed no
differences in neuronal density in the substantia nigra of mice
injected with proteasome inhibitors or the vehicle alone. E
Neurogenesis in P15 mice was unaffected by postnatal proteasome
inhibition, as revealed by doublecortin (DCX) immunostaining.
(TIF)
Figure S3 Proteasome inhibition during early postnatal
development does not induce motor behaviour or
morphological alterations in the spinal cord of adult
mice. A–C, Motor function in adult mice that were treated with
proteasome inhibitors during early life was measured by their
performance in the rotarod (A), treadmill (B) and grip strength (C)
tests. D, Representative Nissl staining microphotograph at lumbar
4–5 level of spinal cord is shown (D).
(TIF)
Table S1 Total object exploration times (in seconds) of
adult mice injected postnatally with the vehicle alone,
MG-132 or lactacystin in each session of a 15-minute OR
memory test. STM, short-term memory; LTM, long-term
memory.
(DOC)
Methods S1 Detailed description of neonatal behaviour-
al tests included in the Fox battery.
(DOC)
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